Merck (NYSE:MRK) is set to report its Q4 2018 earnings on February 1, and we expect the company to post mid-single-digit top line growth and low double-digits earnings growth. This can be attributed to the continued growth in the company's blockbuster drug, Keytruda, along with Gardasil. The ...
Merck (NYSE:MRK) is set to report its Q4 2018 earnings on February 1, and we expect the company to post mid-single-digit top line growth and low double-digits earnings growth. This can be attributed to the continued growth in the company's blockbuster drug, Keytruda, along with Gardasil. The ...
Share this Article
Recommended